Evolus, Inc. Announces Proposed Public Offering of Common Stock
July 16 2018 - 4:01PM
Evolus, Inc. (Nasdaq:EOLS) (“Evolus”) announced today that it has
filed a registration statement on Form S-1 with the U.S. Securities
and Exchange Commission (“SEC”) and commenced a proposed
underwritten public offering of 5,000,000 shares of its common
stock. The offering is expected to consist of 2,500,000 shares to
be offered by Evolus and 2,500,000 shares to be offered by a
selling stockholder of Evolus. In addition, Evolus and the selling
stockholder are expected to grant the underwriters of the offering
an option for a period of 30 days to purchase up to an additional
750,000 shares at the public offering price, less the underwriting
discount. Evolus will not receive any proceeds from the sale of
shares by the selling stockholder. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed.
Cantor Fitzgerald & Co. and Mizuho Securities
USA LLC are acting as joint book-running managers for the offering.
SunTrust Robinson Humphrey, Inc. and JMP Securities LLC are acting
as lead managers. This proposed offering will be made only by means
of a prospectus. A copy of the preliminary prospectus may be
obtained from Cantor Fitzgerald & Co., Attention: Capital
Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by
e-mail at prospectus@cantor.com; or Mizuho Securities USA LLC,
Attention: Equity Capital Markets, 320 Park Ave., New York, New
York 10022, or by e-mail at US-ECM@us.mizuho-sc.com, or by
telephone at (212) 205-7600.
A registration statement relating to these
securities has been filed with the SEC but has not yet become
effective. These securities may not be sold, nor may offers to buy
be accepted, prior to the time the registration statement becomes
effective. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy, nor shall there be any sale
of, these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration
or qualification of these securities under the securities laws of
any such state or jurisdiction.
About Evolus
Evolus is a company dedicated to aesthetic medicine
focused on providing physicians and their patients with expanded
choices in aesthetic treatments and procedures. Evolus’ lead
product candidate, DWP-450, also known by the chemical name
prabotulinumtoxinA, is a 900 kDa purified botulinum toxin type A
complex that is being evaluated for the treatment of moderate to
severe glabellar lines.
Forward-Looking Statements
This press release contains certain forward-looking
statements, including statements with regard to Evolus’ proposed
public offering. Words such as “expects,” “anticipates” and
“intends” or similar expressions are intended to identify
forward-looking statements. These forward-looking statements are
subject to the inherent uncertainties in predicting future results
and conditions and no assurance can be given that the proposed
public offering discussed above will be completed on the terms
described. Completion of the proposed public offering and the terms
thereof are subject to numerous factors, many of which are beyond
the control of Evolus, including, without limitation, failure of
customary closing conditions and the risk factors and other matters
set forth in the prospectus included in the registration statement
in the form last filed with the SEC. Evolus undertakes no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise, except as may be required by law.
Evolus Contacts:
Investor Contact:Brian Johnston, The Ruth Group Tel: +1
646-536-7028Email: IR@Evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024